Erythropoietin for newborns with brain injury from oxygen loss

This Phase 3 trial studies whether erythropoietin (a medicine related to red-blood-cell growth) can improve outcomes for newborns with moderate to severe brain injury after birth. The study focuses on babies born in low- and middle-income countries and aims to reduce harm from this early brain condition.

This trial is for newborn babies who had an oxygen shortage around birth and now have severe brain injury. It aims to test approaches that may help improve outcomes after this kind of early-life brain damage.

This study looks at a blood test that might help check brain injury in newborns who had a lack of oxygen at birth. The test could give doctors more information to help care for your baby.

This early-phase study tests whether using a baby’s own cord blood stem cells is safe and feasible for newborns with brain injury from lack of oxygen around birth. It may help researchers find new ways to treat hypoxic-ischemic encephalopathy (brain injury due to oxygen deprivation) in addition to standard care like cooling.

This early study tests whether giving melatonin to newborns with hypoxic-ischemic encephalopathy (brain injury from not enough oxygen around birth) can help protect the brain while they are cooled (therapeutic hypothermia). It may be most relevant if your baby shows early brain-injury signs and meets specific blood test and birth-history timing criteria.

This trial tests if giving caffeine to newborns who had low oxygen at birth can help protect their brains. It compares caffeine plus standard care to placebo plus standard care for moderate to severe hypoxic ischemic encephalopathy (HIE).